After FIRAPY introduction in 2014, fistuloplasty decrease.
- The total numbers of fistuloplasty from 2011 to 2013 is 197.
- The total numbers of fistuloplasty from 2014 to 2016 is 156.
Reduction of 41 procedure, it’s 21% reduction of fistuloplasty.
FIRAPY reduce the need & frequency of Fistuloplasty
May 1, 2018
FIRAPY is a physical treatment utilizing infrared radiation with longer wavelengths than visible light. This energy, has applications in health promotion and wound healing. FIRAPY is delivered via a device with ceramic plates, placed above an arteriovenous fistula (AVF) during hemodialysis sessions. Studies suggest that FIR enhances blood flow and patency in AVFs, reduces pain from steal syndrome, and inhibits endothelial inflammation, addressing key factors in AVF stenosis and thrombosis.
A study at Raigmore Hospital, Inverness, highlighted FIRAPY's impact on reducing fistuloplasty frequency. Comparing data from 2011-2013 to 2014-2016, after FIRAPY was introduced, showed a 21% reduction in procedures. Individual cases demonstrated extended intervals between fistuloplasties following FIR initiation. Despite barriers like cost, staff training, and patient refusal, FIRAPY therapy proved effective, convenient, and cost-saving, reducing hospital stays for hemodialysis patients with AVF complications.
Patient Selection
- Poor maturation of AVF
- After first or requiring regular fistuloplasty
- Steal Syndrome
- Patients referred from weekly vascular MDT
Application of FIRAPY
- To be used on native AV fistulae only
- Fistula limb must be uncovered
- Applied during every dialysis session, 40 min duration
Result
Conclusion
- FIRAPY used on a regular basis does reduce the need for interventions.
- It is an easy and convenient mode of therapy.
- Cost effective.
- Leads to a reduction in in-patients stays for HD patients due to fistula complication.
Arthur: Dr Susan Stewart
Site: Raigmore Hospital, Inverness, UK
Presented at the 2017 BRS Conference.
Want to know more?
Contact us for more detail
We’re excited to announce that FIRAPY will be exhibiting at the 62nd ERA Congress in Vienna from June 4–7, 2025 ! 📍 Booth No.: X1.200 📅 June 4–7, 2025 📍 Austria Center Vienna This marks FIRAPY’s first European event since the COVID-19 pandemic , making it a special occasion for us to reconnect with partners and professionals across the continent. This year’s congress theme, “Game Changers in Nephrology,” aligns perfectly with FIRAPY’s mission to enhance dialysis care through innovative vascular access management. We look forward to seeing old friends and new collaborators who share our commitment to improving outcomes for dialysis patients. Whether you're already using FIRAPY or exploring its clinical potential, we warmly invite you to visit our booth and connect with our team. Let’s explore how far-infrared therapy is transforming the future of vascular access—together.
From February 28 to March 1, FIRAPY was honored to participate in Dialysis Weekend 2024 in Pattaya, Thailand, at the invitation of our valued partner K2 Thailand . This annual event, hosted by the Nephrology Society of Thailand ( event site ), is a key gathering for nephrology professionals across the country. This occasion marked a milestone for K2 Thailand, as their entire dialysis sales team made their first collective public appearance alongside FIRAPY. The team’s strong presence and professionalism drew significant attention from both clinicians and industry attendees, highlighting the growing interest in FIRAPY's role in dialysis care. A special highlight of the event was the visit from Dr. Suki , a well-known figure in the international nephrology community ( WCN profile ). Dr. Suki stopped by the K2 booth to personally show support and encouragement to the team, reinforcing the collaboration and shared mission of improving vascular access outcomes for dialysis patients.
Meet FIRAPY at Booth i1115a!
